These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17497280)

  • 1. Evaluation on the safety and efficacy of tirofiban in the treatment of acute coronary syndrome.
    Song Y
    J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):142-4. PubMed ID: 17497280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
    N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
    Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
    N Engl J Med; 1998 May; 338(21):1498-505. PubMed ID: 9599104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
    Huynh T; Theroux P; Snapinn S; Wan Y;
    Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
    Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM;
    JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study.
    Théroux P; Alexander J; Pharand C; Barr E; Snapinn S; Ghannam AF; Sax FL
    Circulation; 2000 Nov; 102(20):2466-72. PubMed ID: 11076818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
    Okmen E; Cakmak M; Tartan Z; Cam N
    Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.
    Kim JH; Jeong MH; Rhew JY; Lim JH; Yun KH; Kim KH; Kang DK; Hong SN; Lim SY; Lee SH; Lee YS; Hong YJ; Park HW; Kim W; Ahn YK; Moon Y; Cho JG; Park JC; Kang JC
    Circ J; 2005 Feb; 69(2):159-64. PubMed ID: 15671606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
    N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
    Zhao XQ; Théroux P; Snapinn SM; Sax FL
    Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.
    Circulation; 1997 Sep; 96(5):1445-53. PubMed ID: 9315530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
    Cohen M; Théroux P; Weber S; Laramée P; Huynh T; Borzak S; Diodati JG; Squire IB; Deckelbaum LI; Thornton AR; Harris KE; Sax FL; Lo MW; White HD
    Int J Cardiol; 1999 Dec; 71(3):273-81. PubMed ID: 10636535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
    Cohen M; Théroux P; Borzak S; Frey MJ; White HD; Van Mieghem W; Senatore F; Lis J; Mukherjee R; Harris K; Bigonzi F;
    Am Heart J; 2002 Sep; 144(3):470-7. PubMed ID: 12228784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes.
    Januzzi JL; Hahn SS; Chae CU; Giugliano R; Lewandrowski K; Theroux P; Jang IK
    Am J Cardiol; 2000 Oct; 86(7):713-7. PubMed ID: 11018188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The glycoprotein IIb/IIIa platelet receptor blocker tirofiban, but not heparin, counteracts platelet aggregation in unstable angina pectoris.
    Mattsson E; Martinsson A; Nyqvist O; Rasmanis G; Sylvén C; Karlberg KE
    Am J Cardiol; 1997 Oct; 80(7):938-40. PubMed ID: 9382012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.
    Servoss SJ; Wan Y; Snapinn SM; DiBattiste PM; Zhao XQ; Theroux P; Jang IK; Januzzi JL;
    Am J Cardiol; 2004 Apr; 93(7):843-7. PubMed ID: 15050486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome.
    Mansur Ade P; Roggerio A; Takada JY; Caribé PM; Avakian SD; Strunz CM
    Sao Paulo Med J; 2016 Jan; 134(3):199-204. PubMed ID: 26786608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial.
    Januzzi JL; Snapinn SM; DiBattiste PM; Jang IK; Theroux P
    Circulation; 2002 May; 105(20):2361-6. PubMed ID: 12021221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.